Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Ceribelli M, Tosto FA, Zhang X, Melani CJ, Roschewski M, Beck E, Klumpp-Thomas C, Peer CJ, Wilson KM, Chen L, McKnight C, Michael S, Itkin Z, Shinn P, Figg WD Sr, Wilson WH, Staudt LM, Thomas CJ. Ceribelli M, et al. Among authors: peer cj. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2413372121. doi: 10.1073/pnas.2413372121. Epub 2024 Nov 25. Proc Natl Acad Sci U S A. 2024. PMID: 39585996 Free PMC article.
Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response.
Lee U, Szabova L, Collins VJ, Gordon M, Johnson K, Householder D, Jorgensen S, Lu L, Bassel L, Elloumi F, Peer CJ, Nelson AE, Varriano S, Varma S, Roberts RD, Ohler ZW, Figg WD, Sharan SK, Pommier Y, Heske CM. Lee U, et al. Among authors: peer cj. Front Cell Dev Biol. 2024 Oct 24;12:1462840. doi: 10.3389/fcell.2024.1462840. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39512899 Free PMC article.
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.
Najera SS, Ricketts CJ, Schmidt LS, Medina JI, Saito K, Ileva L, Brender JR, James AM, Peer CJ, Gouker B, Karim BO, Chernova O, Wells C, Wei MH, Yang Y, Zhang X, Klumpp-Thomas C, Travers J, Chen L, Wilson KM, Issaq SH, Figg WD, Difilippantonio S, Kalen JD, Krishna MC, Thomas CJ, Ceribelli M, Heske CM, Crooks DR, Meier JL. Najera SS, et al. Among authors: peer cj. Mol Cancer Ther. 2024 Oct 14. doi: 10.1158/1535-7163.MCT-24-0225. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39397296
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
Hultcrantz M, Hassoun H, Korde N, MacLachlan K, Mailankody S, Patel D, Shah UA, Tan CR, Chung DJ, Lahoud OB, Landau HJ, Scordo M, Shah GL, Giralt SA, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemirovsky D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. Hultcrantz M, et al. Among authors: peer cj. Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1. Blood Cancer J. 2024. PMID: 39300066 Free PMC article. No abstract available.
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, Simard J, Muppidi J, Thomas CJ, Ceribelli M, Tosto FA, Yang Y, Xu W, Davies-Hill T, Pack SD, Peer CJ, Arisa O, Mena E, Lindenberg L, Bergvall E, Portell CA, Farah RJ, Lee ST, Pradhan A, Morrison C, Tadese A, Juanitez AM, Lu C, Jacob A, Simmons H, Figg WD, Steinberg SM, Jaffe ES, Roschewski M, Staudt LM, Wilson WH. Melani C, et al. Among authors: peer cj. N Engl J Med. 2024 Jun 20;390(23):2143-2155. doi: 10.1056/NEJMoa2401532. N Engl J Med. 2024. PMID: 38899693 Free PMC article. Clinical Trial.
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.
Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, Shah U, Tan CR, Chung DJ, Lahoud O, Landau H, Scordo M, Shah GL, Giralt S, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemikovski D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. Hultcrantz M, et al. Among authors: peer cj. Res Sq [Preprint]. 2024 Jun 5:rs.3.rs-4406606. doi: 10.21203/rs.3.rs-4406606/v1. Res Sq. 2024. Update in: Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1 PMID: 38883739 Free PMC article. Updated. Preprint.
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N, Peer CJ, Zhang X, Choo-Wosoba H, Ahmad MI, Lee MJ, Rastogi S, Sato N, Yu Y, Pegna GJ, Steinberg SM, Kalsi SS, Cao L, Figg WD, Trepel JB, Pastan I, FitzGerald D, Alewine C. Skorupan N, et al. Among authors: peer cj. Front Oncol. 2024 Apr 19;14:1386190. doi: 10.3389/fonc.2024.1386190. eCollection 2024. Front Oncol. 2024. PMID: 38706610 Free PMC article.
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, McKnight C, Itkin Z, Sotome H, Hirai H, Calleja E, Wacheck V, Gouker B, Peer CJ, Corvalan N, Milewski D, Kim YY, Figg WD, Edmondson EF, Thomas CJ, Difilippantonio S, Wei JS, Khan J. Wu JT, et al. Among authors: peer cj. Cancers (Basel). 2023 Aug 9;15(16):4034. doi: 10.3390/cancers15164034. Cancers (Basel). 2023. PMID: 37627061 Free PMC article.
148 results